CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

Thumbnail
View/Open
Date
2018-09-01
ICR Author
Author
Gillison, ML
Blumenschein, G
Fayette, J
Guigay, J
Colevas, AD
Type
Journal Article
Metadata
Show full item record
Abstract
Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.
URI
https://repository.icr.ac.uk/handle/internal/3036
DOI
Collections
Subject
Humans
Head and Neck Neoplasms
Neoplasm Recurrence, Local
Time Factors
Antineoplastic Agents, Immunological
Nivolumab
Research team
Targeted Therapy
Language
eng
Date accepted
2018-03-06
License start date
2018-09
Citation
The oncologist, 2018, 23 (9), pp. 1079 - 1082
Publisher
WILEY